KRAS and lung carcinoma: We first tested the time-dependent effect of the KRASG12C inhibitor ARS-1620 on the expression of KRASG12C, ERK phosphorylation, accumulation of active KRAS (KRAS-GTP), and the cell cycle of KRASG12C-mutant lung cancer cells.